Age as an independent prognostic factor in patients with glioblastoma: A radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison

Journal of Neuro-Oncology

Volumn 104, Issue 1, 2011, Pages 351-356

  Siker, Malika L ^a   Wang, Meihua ^b   Porter, Kimberly ^c   Nelson, Diana F ^d   Curran, Walter J ^e   Michalski, Jeff M ^f   Souhami, Luis ^g   Chakravarti, Arnab ^h   Yung, W K Alfred ⁱ   Delrowe, John ^j   Coughlin, Christopher T ^k   Mehta, Minesh P ^l  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c AMERICAN COLLEGE OF SURGEONS   (United States)

^d MAYO CLINIC   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j MONTEFIORE MEDICAL CENTER   (United States)

^k DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Age factors; Glioblastoma; Prognostic factors; Survival; Young adult

Indexed keywords

ADULT; AGE; AMERICAN COLLEGE OF SURGEONS NATIONAL CANCER DATA BASE; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; DATA BASE; FEMALE; GLIOBLASTOMA; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGE FACTORS; AGING; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PROGNOSIS; RADIATION ONCOLOGY; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; TIME FACTORS; YOUNG ADULT;

EID: 80052772289     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0500-6     Document Type: Article

References (30)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 18287387 10.3322/CA.2007.0010 (Pubitemid 351521864)
2. Central Brain Tumor Registry of the United States (2005) Statistical report: primary brain tumors in the United States, 1998-2002. http://www.cbtrus.org/reports/reports.html. Accessed 20 Sept 2007
3. R Stupp ME Hegi WP Mason MJ van den Bent MJ Taphoorn RC Janzer SK Ludwin A Allgeier B Fisher K Belanger P Hau AA Brandes J Gijtenbeek C Marosi CJ Vecht K Mokhtari P Wesseling S Villa E Eisenhauer T Gorlia M Weller D Lacombe JG Cairncross RO Mirimanoff 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 19269895 10.1016/S1470-2045(09)70025-7 1:CAS:528: DC%2BD1MXlsVKhs74%3D
4. WJ Curran Jr CB Scott J Horton JS Nelson AS Weinstein AJ Fischbach CH Chang M Rotman SO Asbell RE Krisch, et al. 1993 Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials J Natl Cancer Inst 85 704 710 8478956 10.1093/jnci/85.9.704 (Pubitemid 23133591)
5. AZ Latif D Signorini A Gregor R Grant JW Ironside IR Whittle 1998 Application of the MRC brain tumour prognostic index to patients with malignant glioma not managed in randomised control trial J Neurol Neurosurg Psychiatry 64 747 750 9647303 10.1136/jnnp.64.6.747 1:STN:280:DyaK1czgvFGiug%3D%3D (Pubitemid 28274408)
6. CB Scott C Scarantino R Urtasun B Movsas CU Jones JR Simpson AJ Fischbach WJ Curran Jr 1998 Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06 Int J Radiat Oncol Biol Phys 40 51 55 9422557 10.1016/S0360-3016(97)00485-9 1:STN:280:DyaK1c%2FotlShsg%3D%3D (Pubitemid 28027566)
7. RO Mirimanoff T Gorlia W Mason MJ Van den Bent RD Kortmann B Fisher M Reni AA Brandes J Curschmann S Villa G Cairncross A Allgeier D Lacombe R Stupp 2006 Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial J Clin Oncol 24 2563 2569 16735709 10.1200/JCO.2005.04.5963 1:CAS:528:DC%2BD28XmtVOmt70%3D (Pubitemid 46630635)
8. D Senger JG Cairncross PA Forsyth 2003 Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype? Cancer J 9 214 221 12952306 10.1097/00130404-200305000-00009
9. BK Kleinschmidt-DeMasters L Meltesen L McGavran KO Lillehei 2006 Characterization of glioblastomas in young adults Brain Pathol 16 273 286 17107596 10.1111/j.1750-3639.2006.00029.x 1:CAS:528:DC%2BD2sXkslKltw%3D%3D
10. C Ulutin M Fayda G Aksu O Cetinayak O Kuzhan F Ors M Beyzadeoglu 2006 Primary glioblastoma multiforme in younger patients: a single-institution experience Tumori 92 407 411 17168433 (Pubitemid 44861776)
11. C Sarkar S Sinha MC Sharma R Kumar VS Mehta 2004 Supratentorial glioblastoma in adults: identification of subsets and their clinical correlation Brain Tumor Pathol 21 7 12 15696962 10.1007/BF02482170 1:CAS:528: DC%2BD2MXht12hu73J (Pubitemid 38915176)
12. PE McKeever L Junck MS Strawderman M Blaivas A Tkaczyk MA Cates M Yan L Li 2001 Proliferation index is related to patient age in glioblastoma Neurology 56 1216 1218 11342691 1:STN:280:DC%2BD3MzntFamtw%3D%3D (Pubitemid 32405719)
13. ML Simmons KR Lamborn M Takahashi P Chen MA Israel MS Berger T Godfrey J Nigro M Prados S Chang FG Barker II K Aldape 2001 Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients Cancer Res 61 1122 1128 11221842 1:CAS:528: DC%2BD3MXhsFSqs7w%3D (Pubitemid 32174434)
14. JA Kraus N Glesmann M Beck D Krex T Klockgether G Schackert U Schlegel 2000 Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme J Neurooncol 48 89 94 11083071 10.1023/A:1006402614838 1:STN:280:DC%2BD3M7kt1GgtQ%3D%3D
15. M Salvati L Cervoni M Artico R Caruso FM Gagliardi 1998 Long-term survival in patients with supratentorial glioblastoma J Neurooncol 36 61 64 9525826 10.1023/A:1017926603341 1:STN:280:DyaK1c7osVOnsg%3D%3D (Pubitemid 28230653)
16. KL Chandler MD Prados M Malec CB Wilson 1993 Long-term survival in patients with glioblastoma multiforme Neurosurgery 32 716 720 8388081 10.1227/00006123-199305000-00003 1:STN:280:DyaK3s3mtFCrtg%3D%3D (discussion 720) (Pubitemid 23134013)
17. M Salcman H Scholtz RS Kaplan S Kulik 1994 Long-term survival in patients with malignant astrocytoma Neurosurgery 34 213 219 8177380 10.1227/00006123- 199402000-00002 1:STN:280:DyaK2c3jt1CisQ%3D%3D (discussion 219-220)
18. JN Scott NB Rewcastle PM Brasher D Fulton NA Hagen JA MacKinnon G Sutherland JG Cairncross P Forsyth 1998 Long-term glioblastoma multiforme survivors: a population-based study Can J Neurol Sci 25 197 201 9706720 1:STN:280:DyaK1cznt1Siug%3D%3D (Pubitemid 28368794)
19. JN Scott NB Rewcastle PM Brasher D Fulton JA MacKinnon M Hamilton JG Cairncross P Forsyth 1999 Which glioblastoma multiforme patient will become a long-term survivor? A population-based study Ann Neurol 46 183 188 10443883 10.1002/1531-8249(199908)46:2<183::AID-ANA7>3.0.CO;2-7 1:STN:280:DyaK1MzntFCrsQ%3D%3D (Pubitemid 29382874)
20. D Krex B Klink C Hartmann A von Deimling T Pietsch M Simon M Sabel JP Steinbach O Heese G Reifenberger M Weller G Schackert 2007 Long-term survival with glioblastoma multiforme Brain 130 2596 2606 17785346 10.1093/brain/awm204 (Pubitemid 47511715)
21. U Sure D Ruedi O Tachibana Y Yonekawa H Ohgaki P Kleihues ME Hegi 1997 Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas J Neuropathol Exp Neurol 56 782 789 9210874 1:CAS:528:DyaK2sXkslaisr0%3D (Pubitemid 27280188)
22. M Szybka J Bartkowiak K Zakrzewski L Polis P Liberski R Kordek 2003 Microsatellite instability and expression of DNA mismatch repair genes in malignant astrocytic tumors from adult and pediatric patients Clin Neuropathol 22 180 186 12908754 1:STN:280:DC%2BD3szntl2qsg%3D%3D (Pubitemid 36869992)
23. M Bredel IF Pollack RL Hamilton CD James 1999 Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood Clin Cancer Res 5 1786 1792 10430083 1:CAS:528:DyaK1MXltVCqt78%3D (Pubitemid 29334460)
24. T Sung DC Miller RL Hayes M Alonso H Yee EW Newcomb 2000 Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas Brain Pathol 10 249 259 10764044 10.1111/j.1750-3639.2000.tb00258.x 1:CAS:528:DC%2BD3cXivVyhurs%3D (Pubitemid 30181093)
25. C Raffel L Frederick JR O'Fallon P Atherton-Skaff A Perry RB Jenkins CD James 1999 Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations Clin Cancer Res 5 4085 4090 10632344 1:CAS:528:DC%2BD3cXlsV2hug%3D%3D (Pubitemid 30013789)
26. IF Pollack SD Finkelstein J Burnham EJ Holmes RL Hamilton AJ Yates JL Finlay R Sposto 2001 Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort Cancer Res 61 7404 7407 11606370 1:CAS:528:DC%2BD3MXnvFShs7o%3D (Pubitemid 32995024)
27. IF Pollack SD Finkelstein J Burnham RL Hamilton AJ Yates EJ Holmes JM Boyett JL Finlay 2003 Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: results from the CCG-945 cohort Pediatr Neurosurg 39 114 121 12876389 10.1159/000071647 (Pubitemid 36928679)
28. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
29. A Bleyer 2007 Young adult oncology: the patients and their survival challenges CA Cancer J Clin 57 242 255 17626120 10.3322/canjclin.57.4.242 (Pubitemid 47312083)
30. A Bleyer A Viny R Barr 2006 Cancer in 15- to 29-year-olds by primary site Oncologist 11 590 601 16794238 10.1634/theoncologist.11-6-590 (Pubitemid 43967614)